KYNTRA BIO Stock Price, News & Analysis
Company Description
KYNTRA BIO (NASDAQ: KYNB) is a publicly traded biotechnology company in the Pharmaceutical Preparations sector. The company has a market capitalization of $28.4M, ranking #5,959 among all listed U.S. companies by market cap.
KYNB stock has declined 26.2% over the past year. Shares last traded at $7.01.
On a trailing twelve-month basis, KYNTRA BIO reported revenue of $6.4M with net income of $183.5M and diluted earnings per share of $45.37. The company operates at a net profit margin of 2848.6%.
This page provides a comprehensive overview of KYNB stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
KYNTRA BIO (KYNB) stock last traded at $7.01. Over the past 12 months, the stock has lost 26.2%. At a market capitalization of $28.4M, KYNB is classified as a micro-cap stock with approximately 4.0M shares outstanding.
Latest News
KYNTRA BIO has 4 recent news articles. Of the recent coverage, 3 articles coincided with positive price movement and 1 with negative movement. Key topics include earnings, earnings date, conferences. View all KYNB news →
SEC Filings
KYNTRA BIO has filed 5 recent SEC filings, including 2 Form 4, 1 Form 10-K, 1 Form 8-K, 1 Form SCHEDULE 13G/A. The most recent filing was submitted on March 16, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all KYNB SEC filings →
Financial Highlights
KYNTRA BIO generated $6.4M in revenue over the trailing twelve months, retaining a 91.4% gross margin, operating income reached -$45.9M (-712.7% operating margin), and net income was $183.5M, reflecting a 2848.6% net profit margin. Diluted earnings per share stood at $45.37. The company generated -$4.8M in operating cash flow. With a current ratio of 3.39, the balance sheet reflects a strong liquidity position.
Upcoming Events
Phase 2 interim analysis
Phase 2 monotherapy interim analysis
KYNTRA BIO has 2 upcoming scheduled events. The next event, "Phase 2 interim analysis", is scheduled for July 1, 2026 (in 88 days). Investors can track these dates to stay informed about potential catalysts that may affect the KYNB stock price.
Short Interest History
Short interest in KYNTRA BIO (KYNB) currently stands at 113.1 thousand shares, up 1.1% from the previous reporting period, representing 2.8% of the float. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for KYNTRA BIO (KYNB) currently stands at 4.0 days, up 35.6% from the previous period. This days-to-cover ratio represents a balanced liquidity scenario for short positions. The days to cover has decreased 24.9% over the past year, suggesting improved liquidity for short covering. The ratio has shown significant volatility over the period, ranging from 2.9 to 5.3 days.
KYNB Company Profile & Sector Positioning
KYNTRA BIO (KYNB) operates in the Biotechnology industry within the broader Pharmaceutical Preparations sector and is listed on the NASDAQ.